BV6
|
- ₹0
- Product name: BV6
- CAS: 1001600-56-1
- MF: C70H96N10O8
- MW: 1205.57
- EINECS:
- MDL Number:MFCD28168021
- Synonyms:4,4'-(1,6-Hexanediyl)bis[N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-L-prolyl-beta-phenyl-L-phenylalaninamide;BV6;N,N'-(hexane-1,6-diyl)bis(1-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-L-prolyl-beta-phenyl-L-phenylalaninamide):trifluoroacetic acid(1:x);CHEBI:47924;CHEBI:47924; BV-6 BV 6;CS-2877;CS-1501;BV-6;BV6
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Boiling point :1376.7±65.0 °C(Predicted)
Density :1.177±0.06 g/cm3(Predicted)
storage temp. :Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility :≥60.28 mg/mL in DMSO; insoluble in H2O; ≥12.6 mg/mL in EtOH with ultrasonic
form :solid
pka :12.89±0.20(Predicted)
color :White to off-white
Density :1.177±0.06 g/cm3(Predicted)
storage temp. :Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility :≥60.28 mg/mL in DMSO; insoluble in H2O; ≥12.6 mg/mL in EtOH with ultrasonic
form :solid
pka :12.89±0.20(Predicted)
color :White to off-white
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
BV6 is a bivalent Smac mimetic and an antagonist of the inhibitor of apoptosis (IAP) proteins that binds to IAP1 and XIAP (Kds = 0.46 and 1.3 nM, respectively). It induces autoubiquitination and proteasomal degradation of IAP1 and XIAP in MDA-MB-231 cells when used at a concentration of 5 μM. BV6 (4 μM) induces NF-κB activation and TNF-dependent apoptosis in A2058 and MDA-MB-231 cells. It enhances radiosensitization and increases apoptosis in HCC193 and H460 non-small cell lung cancer (NSCLC) cell lines. BV6 (1 μM) induces cell death in a panel of 40 primary, patient-derived B cell precursor acute lymphoblastic leukemia (BCP-ALL) samples in a TNF-dependent manner. In vivo, BV6 (10 mg/kg) increases survival and the time to relapse in a high-risk BCP-ALL patient-derived xenograft (PDX) mouse model.Related product price
- Doxorubicin hydrochloride
₹4491-89190 - Rapamycin
₹4194-370089 - MG-132
₹6600.01-40810